# An Open-Label Study To Assess The Pharmacokinetics, Safety And Toleration Of Vfend®; Following Multiple Dosing With Vfend

> **NCT00150319** · PHASE1,PHASE2 · TERMINATED · sponsor: **Pfizer** · enrollment: 1 (actual)

## Conditions studied

- Kidney Failure

## Interventions

- **DRUG:** Vfend®; I.V.

## Key facts

- **NCT ID:** NCT00150319
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-06
- **Primary completion:** 2005-10
- **Final completion:** 2005-10
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** See Detailed Description
- **Last updated:** 2008-09-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00150319

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00150319, "An Open-Label Study To Assess The Pharmacokinetics, Safety And Toleration Of Vfend®; Following Multiple Dosing With Vfend". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00150319. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*